Imported Drug Shelf Life:12 Month Rule

The Ministry of Health of the Union has changed the shelf-life provisions of the medicines which are to be imported into India from a minimum of 60% of residual shelf life to 12 months as the minimum shelf life requirement. This move would increase the availability of the medicines which are to be imported into India.

This would particularly help the importers, distributors, and the hospitals dealing with specialized medicines.

What Has Changed in the Imported Drug Shelf-Life Rule?

According to the previous requirement, in general, imported medicines had to ensure at least 60% of the total life period of the medicine approved by the authorities at the moment of its importation into India.

In case a drug had a total life period of 24 months, then at the moment of its importation, it should have at least 14.4 months remaining.

The new requirement does not base on a calculation of the period left according to the percentage but on the period which should be equal to 12 months for all medicines which are imported.

Thus, the imported medicines will have to have at least one year of the shelf life left at the moment of importation.

Why Has the Government Revised the Requirement?

The 60% provision above might cause challenges for the importer where the product being imported has a shorter shelf-life or experiences delay in transit.

Products will be disqualified from import even if they have adequate shelf life left to consume.

The new provision aims at simplifying the process and avoiding any unnecessary supply disruption.

This may help in getting the specialized medicines as well which include products for intensive care as well as those that are not manufactured locally in enough quantities.

Nevertheless, the new provision does not imply that any medicines with inferior quality and poor storage conditions can enter the Indian market.

What Does the Change Mean for Pharmaceutical Companies?

The new regulation would offer increased operational flexibility for pharmaceutical companies importing and distributing drugs.

It will be easier for firms to ship and handle their inventory without any risk of ineligibility due to the earlier percentage computation.

Patients and hospitals would be the other group that would benefit from increased availability of some imported drugs where there are no substitutes locally.

Nevertheless, importers would still be expected to meet India’s regulatory requirements for the imported pharmaceuticals.

Patient Safety Remains a Priority

The need for shelf life is necessary since medications can degrade after their expiry dates, and hence their efficacy is reduced.

A set 12-month residual requirement would make compliance easy to gauge, but still proper storage, transport, and quality assurance is paramount.

The new policy has emerged as an effort by the government to strike a balance between availability and safety of medication.

The policy will be effective depending on its implementation, supervision, and the capacity of importers to sustain the quality of medications from manufacture to distribution.

The main hope for patients would be that the new policy increases the availability of medicine without compromising on their safety or efficacy.